ReviewInternational journal of endocrinology2014
Anaplastic Thyroid Carcinoma: Current Treatments and Potential New Therapeutic Options with Emphasis on TfR1/CD71.
Review in International journal of endocrinology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- ESR Essentials: thyroid imaging-practice recommendations by the European Society of Head and Neck Radiology.European radiology · 2026Guideline
- LINC01929 promotes breast cancer progression through a TFRC-associated ferroptosis pathway.Cell death discovery · 2026Article
- Cancer-associated fibroblasts as a potential therapeutic target for thyroid cancers.International journal of surgery (London, England) · 2026Review
- Glioblastoma mesenchymal subtype enhances antioxidant defence to reduce susceptibility to ferroptosis.Scientific reports · 2024Article
- circ-TFRC downregulation suppresses ovarian cancer progression via miR-615-3p/IGF2 axis regulation.Cancer cell international · 2024Article
- Anaplastic thyroid cancer cells reduce CD71 levels to increase iron overload tolerance.Journal of translational medicine · 2023Article
- Knockdown of TFRC suppressed the progression of nasopharyngeal carcinoma by downregulating the PI3K/Akt/mTOR pathway.Cancer cell international · 2023Article
- Engineering a HEK-293T exosome-based delivery platform for efficient tumor-targeting chemotherapy/internal irradiation combination therapy.Journal of nanobiotechnology · 2022Article
- Gold-Based Nanoplataform for the Treatment of Anaplastic Thyroid Carcinoma: A Step Forward.Cancers · 2021Article
- Antibodies Targeting the Transferrin Receptor 1 (TfR1) as Direct Anti-cancer Agents.Frontiers in immunology · 2021Review
- Anaplastic thyroid carcinoma combined with sclerosing mucoepidermoid carcinoma with eosinophilia: A case report.Medicine · 2020Article
- TFRC promotes epithelial ovarian cancer cell proliferation and metastasis via up-regulation of AXIN2 expression.American journal of cancer research · 2020Article
- Abemaciclib (CDK4/6 Inhibitor) Blockade Induces Cytotoxicity in Human Anaplastic Thyroid Carcinoma Cells.Reports of biochemistry & molecular biology · 2020Article
- miR-19a Is Involved In Progression And Malignancy Of Anaplastic Thyroid Cancer Cells.OncoTargets and therapy · 2019Article
- MiR-19a Overexpression in FTC-133 Cell Line Induces a More De-Differentiated and Aggressive Phenotype.International journal of molecular sciences · 2018Article
- Transferrin receptor-targeted HMSN for sorafenib delivery in refractory differentiated thyroid cancer therapy.International journal of nanomedicine · 2018Article
- Enhanced cytotoxic effect of camptothecin nanosponges in anaplastic thyroid cancer cells in vitro and in vivo on orthotopic xenograft tumors.Drug delivery · 2017Article
- Mouse models of thyroid cancer: A 2015 update.Molecular and cellular endocrinology · 2016Review
- Optical Control of CRISPR/Cas9 Gene Editing.Journal of the American Chemical Society · 2015Article
- Modeling anaplastic thyroid carcinoma in the mouse.Hormones & cancer · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anaplastic thyroid carcinoma (ATC) is one of the most aggressive human cancers. Actually, ATC is refractory to conventional therapies, including surgery, chemotherapy, radiotherapy, and radioiodine ((131)I) therapy. Accordingly, genetic and molecular characterizations of ATC have been frequently and periodically reviewed in order to identify potential biological markers exploitable for target therapy. This review briefly focuses on main molecular events that characterize ATC and provides an update about preclinical studies. In addition, the overexpression of transferrin receptor 1 (TfR1/CD71) by neoplastic cells of ATC is emphasized in that it could represent a potential therapeutic target. In this regard, new therapeutic approaches based on the use of monoclonal or recombinant antibodies, or transferrin-gallium-TfR1/CD71 molecular complexes, or lastly small interfering RNAs (siRNAs) are proposed.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.